Table_4_Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study.docx
In the last decade, targeting the immune system became a promising therapy in advanced lung cancer stages. However, in a clinical follow-up, patient responses to immune checkpoint inhibitors widely differ. Peripheral blood is a minimally invasive source of potential biomarkers to explain these differences. We blindly analyzed serum samples from 139 patients with non-small cell lung cancer prior to anti-PD-1 or anti-PD-L1 therapies to assess whether baseline levels of albumin (ALB), alpha-1 acid glycoprotein (AGP), alpha1-antitrypsin (AAT), alpha2-macroglobulin (A2M), ceruloplasmin (CP), haptoglobin (HP), alpha1-antichymotrypsin (ACT), serum amyloid A (SAA), and high-sensitivity C-reactive protein (hs-CRP), have a predictive value for immunotherapy success. Disease progression-free survival (PFS) was calculated based on RECIST 1.1 criteria. A multivariate Cox regression analysis, including serum levels of acute-phase proteins and clinical parameters, revealed that higher pre-therapeutic levels of HP and CP are independent predictors of a worse PFS. Moreover, a combined panel of HP and CP stratified patients into subgroups. We propose to test this panel as a putative biomarker for assessing the success of immunotherapy in patients with NSCLC.
History
References
- https://doi.org//10.1186/s40425-018-0319-9
- https://doi.org//10.1038/s41568-019-0116-x
- https://doi.org//10.1056/NEJMoa1809064
- https://doi.org//10.1016/S0140-6736%2818%2932409-7
- https://doi.org//10.1200/JCO.18.00149
- https://doi.org//10.1200/JCO.18.00149
- https://doi.org//10.1056/NEJMoa1910231
- https://doi.org//10.1186/s12943-020-01260-z
- https://doi.org//10.1155/2018/6984948
- https://doi.org//10.1186/s40425-016-0153-x
- https://doi.org//10.1016/j.cllc.2021.03.006
- https://doi.org//10.3389/fonc.2021.622076
- https://doi.org//10.1016/j.lungcan.2006.03.012
- https://doi.org//10.1016/j.lungcan.2008.04.011
- https://doi.org//10.1097/JTO.0b013e3181da78f9
- https://doi.org//10.1002/1097-0142%2819860501%2957%3A9%3C1783%3A%3AAID-CNCR2820570912%3E3.0.CO;2-L
- https://doi.org//10.1002/pmic.200300514
- https://doi.org//10.1186/1471-2407-5-110
- https://doi.org//10.1002/elps.200700246
- https://doi.org//10.1038/sj.bjc.6605700
- https://doi.org//10.1016/j.ejca.2016.03.081
- https://doi.org//10.1371/journal.pone.0051862
- https://doi.org//10.1016/S1470-2045%2816%2930406-5
- https://doi.org//10.1097/FTD.0000000000000460
- https://doi.org//10.21037/tlcr.2019.04.14
- https://doi.org//10.1158/1078-0432.CCR-20-3054
- https://doi.org//10.21873/invivo.11462
- https://doi.org//10.1007/s11523-018-0599-5
- https://doi.org//10.1159/000464328
- https://doi.org//10.1007/s00262-020-02515-w
- https://doi.org//10.1016/j.cell.2011.02.013
- https://doi.org//10.1016/j.immuni.2019.06.025
- https://doi.org//10.1016/S1470-2045%2814%2970263-3
- https://doi.org//10.3390/cancers12082319
- https://doi.org//10.1038/nature13954
- https://doi.org//10.18632/oncotarget.21602
- https://doi.org//10.1080/0284186X.2017.1415460
- https://doi.org//10.1136/esmoopen-2019-000531
- https://doi.org//10.1007/s13277-016-5122-y
- https://doi.org//10.1136/bmjopen-2019-034010
- https://doi.org//10.1096/fj.02-0019fje
- https://doi.org//10.1016/j.cccn.2004.03.016
- https://doi.org//10.1002/pmic.200700433
- https://doi.org//10.1016/j.prp.2009.04.007
- https://doi.org//10.1038/bjc.1992.58
- https://doi.org//10.1016/j.lungcan.2018.01.012
- https://doi.org//10.1016/S0009-9120%2800%2900048-5
- https://doi.org//10.1016/j.biocel.2015.11.006
- https://doi.org//10.1186/s12885-017-3814-3
- https://doi.org//10.4149/318_151001N512
- https://doi.org//10.1016/S0167-4838%2800%2900153-9
- https://doi.org//10.4103/0975-7406.76489
- https://doi.org//10.1016/j.urology.2009.08.029
CC BY 4.0